^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CXCL2 elevation

i
Other names: C-X-C Motif Chemokine Ligand 2, Macrophage Inflammatory Protein 2-Alpha, Chemokine (C-X-C Motif) Ligand 2, Growth-Regulated Protein Beta, C-X-C Motif Chemokine 2, GRO2 Oncogene, MIP2-Alpha, Gro-Beta, SCYB2, GRO2, Melanoma Growth Stimulatory Activity Beta, MGSA Beta, CINC-2a, MGSA-B, MIP-2a, MIP2, GROB
Entrez ID:
3ms
Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function. (PubMed, Inflamm Bowel Dis)
Anti-IL-18 neoepitope mAb ameliorates acute and chronic colitis, suggesting that this mAb will be an innovative therapeutic option for IBD.
Preclinical • Journal
|
IFNG (Interferon, gamma) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CLDN1 (Claudin 1) • CXCL2 (C-X-C Motif Chemokine Ligand 2) • OCLN (Occludin)
|
CXCL2 elevation • IL18 expression
4ms
Advanced Biphasic Pulsed Electric Field (PEF) Stimulates a More Favorable Immune Response Profile versus Irreversible Electroporation (IRE) upon Ablation of Murine Breast Cancer (SIR 2024)
The proprietary Aliya PEF ablation modality resulted in important differences in post-ablation intratumoral cytokines that indicate distinct effects in the tumor microenvironment between the ablation technologies. This resulted in increased intratumoral immune cell populations for Aliya PEF relative to Sham or IRE. These data suggest that Aliya PEF generates a uniquely favorable immunostimulatory profile versus IRE in a murine model.
Preclinical • Metastases
|
IL2 (Interleukin 2) • CCL11 (C-C Motif Chemokine Ligand 11) • CSF2 (Colony stimulating factor 2) • CCL3 (C-C Motif Chemokine Ligand 3) • IL13 (Interleukin 13) • IL7 (Interleukin 7)
|
CXCL2 elevation
4ms
Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation (ASH 2023)
5 months). Clinical, functional and mechanistic studies are required to complete these findings.
Clinical
|
TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
|
TP53 mutation • DNMT3A mutation • TET2 mutation • PPM1D mutation • CXCL2 elevation
4ms
Biological effects of molybdenum(IV) sulfide nanoparticles and microparticles in the rat after repeated intratracheal administration. (PubMed, J Appl Toxicol)
In summary, it was shown that nanosized and microsized MoS can trigger dose-dependent inflammatory reactions in the lungs of rats after multiple intratracheal instillation irrespective of the animal sex. Some evidence indicates a higher lung pro-inflammatory potential of the microform.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
CXCL2 elevation
5ms
Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy. (PubMed, Cell Death Dis)
The combination of targeting the CXCL8 pathway and blocking the PD-1 pathway synergistically increased the tumor immune response and inhibited tumor progression. Thus, our results highlight the molecular mechanisms and translational significance of CAAs in tumor progression and immune ecosystem regulatory effects and provide a better understanding of the potential clinical benefit of targeting CAA-derived CXCL8 in antitumor immunity and as a new therapeutic moiety in TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD4 (CD4 Molecule)
|
PD-L1 expression • CXCL2 elevation
7ms
Interferon-gamma treatment of human umbilical cord mesenchymal stem cells can significantly reduce damage associated with diabetic peripheral neuropathy in mice. (PubMed, Curr Stem Cell Res Ther)
Interferon-gamma treatment of umbilical cord mesenchymal stem cells enhanced osteogenic differentiation, adipogenic differentiation, and proliferative potential. It can enhance the ability of human umbilical cord mesenchymal stem cells to alleviate damage to diabetic nerve fibers and Schwann cells, in addition to improving the neurological function of diabetic mice.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CASP3 (Caspase 3) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2) • IL1B (Interleukin 1, beta) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • BGLAP (Bone Gamma-Carboxyglutamate Protein)
|
BCL2 expression • IFNG expression • BAX expression • CXCL2 elevation
1year
PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. (PubMed, Signal Transduct Target Ther)
Furthermore, C-X-C motif chemokine receptor 2 (CXCR2) antagonist SB225002 enhanced the docetaxel (DTX) effects on tumor growth by decreasing BCSCs in CCL20-expressing tumors. These findings elucidated how CCL20 modulated the TME to promote cancer development, indicating a new therapeutic strategy by interfering with the interaction between PMN-MDSCs and BCSCs in breast cancer, especially in CCL20-expressing breast cancer.
Journal
|
NOTCH1 (Notch 1) • CCL20 (C-C Motif Chemokine Ligand 20) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CCR6 (C-C Motif Chemokine Receptor 6) • HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1)
|
CXCL2 elevation
|
docetaxel
over1year
Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS) (ASH 2022)
Pts were randomized to azacitidine (AZA) monotherapy or AZA + anti-PDL1 antibody durvalumab, which did not improve clinical outcomes (Zeidan et al. Although an increased population of cytotoxic T-cells suggest an activated immune system, we also found the upregulation of inhibitory immune checkpoints such as PD-L1 in TP53-mut pts suggesting an immunosuppressive microenvironment as a potential contributor to the poor prognosis of TP53-M AML and MDS with similar findings across disease type (HR-MDS vs AML) and mono- vs multi-hit TP53 mutation status.
PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • TP53 mutation • TP53 wild-type • TP53 expression • CXCL2 elevation
|
Imfinzi (durvalumab) • azacitidine
almost2years
Loss of RNA binding protein HuD facilitates the production of the senescence-associated secretory phenotype. (PubMed, Cell Death Dis)
Exposure to γ-irradiation induced cellular senescence in N2a cells and HuD knockdown facilitated stress-induced cellular senescence. Our results reveal that HuD acts as a novel regulator of CCL2 expression, and its aberrant expression may contribute to cellular senescence by regulating SASP production.
Journal
|
IL6 (Interleukin 6) • CCL20 (C-C Motif Chemokine Ligand 20) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
CXCL2 elevation
2years
Humoral and cellular correlates of a novel immune-related adverse event and its treatment. (PubMed, J Immunother Cancer)
It also demonstrates the biologic effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management.
Journal • Adverse events • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
CXCL2 elevation
2years
Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. (PubMed, Gut)
Our study unveils a novel crosstalk between TANs and CRC cells involving the secreted AGR2-CD98hc-xCT axis that promotes metastasis and impacts the outcomes of patients with CRC.
Journal
|
SLC3A2 (Solute Carrier Family 3 Member 2) • AGR2 (Anterior gradient 2) • SLC7A5 (Solute Carrier Family 7 Member 5) • TGFB1 (Transforming Growth Factor Beta 1) • CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
CXCL2 elevation
over2years
ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma. (PubMed, Oncogene)
This effect was reversed by the PI3K selective inhibitor LY294002. Collectively, ITLN1 synergistically suppressed IL-17D and CXCL2-mediated tumor vascularization, bone marrow derived EPC recruitment, as well as MDSCs generation and trafficking. Thus, ITLN1 potentially serves as a critical prognostic and therapeutic target for CRC.
Journal
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NOS2 (Nitric Oxide Synthase 2) • RELA (RELA Proto-Oncogene)
|
CXCL2 elevation
|
LY294002
almost3years
Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma. (PubMed, Front Immunol)
Our study demonstrates that overexpression of PDCD10 in GBM recruits and activates microglia/macrophages, which in turn promotes tumor progression. CXCL2-CXCR2 signaling mediated by PDCD10 is potentially involved in the crosstalk between GBM cells and GAMs.
Journal
|
CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
CXCL2 elevation
over3years
Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma. (PubMed, World J Gastroenterol)
SAA1 is downregulated in the liver tumor, and it is closely involved in the progression of HCC. Lower SAA1 expression indicates lower survival rate, especially for those patients without hepatitis virus infection. Lower SAA1 expression also suggests lower immune infiltrating cells, especially for those with immune cells exerting anti-tumor immune function. SAA1 expression is closely associated with the anti-tumor immune pathways.
Journal • PD(L)-1 Biomarker
|
TP53 (Tumor protein P53) • SAA1 (Serum Amyloid A1) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
TP53 mutation • TP53 expression • CXCL2 elevation • TILs
over3years
[VIRTUAL] Silica Nanoparticle Induced Lung Injury in Mice: Dissecting Relative Contribution of Its Size and Surface Modification (ATS-I 2020)
While 50nm-plain and 50nm-NH 2 were phagocytosed by alveolar macrophages and RAW264.7 cells with comparable rate, chemokine expression including TNFα and MIP2 were significantly attenuated in RAW264.7 cells with 50nm-NH 2 compared to 50nm-plain. [Discussion] Our results suggest that poorer uptake with larger particular size or dimmed chemokine expression after uptake of amine modified particles by alveolar macrophages can be attributed to milder injury observed in murine lung.
Preclinical
|
TNFA (Tumor Necrosis Factor-Alpha)
|
CXCL2 elevation
almost4years
[VIRTUAL] Low-dose targeted radionuclide therapy has favorable local and systemic effects on immune populations in a murine prostate cancer model (AACR-II 2020)
These data suggest that low-dose TRT is superior for immunomodulation because, although it has little effect on tumor growth, it increases intratumoral CD8+ T cell infiltration while avoiding deleterious systemic immune effects. We hypothesize that immunomodulatory TRT combined with checkpoint blockade will improve anti-tumor efficacy compared to high-dose TRT.
Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CCL5 (Chemokine (C-C motif) ligand 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
PD-1 expression • LAG3 expression • CXCL2 elevation
almost4years
Tripterine Restrains the Aggressiveness of Hepatocellular Carcinoma Cell via Regulating miRNA-532-5p/CXCL2 Axis. (PubMed, Onco Targets Ther)
The expression of CXCL2 was distinctly decreased and miR-532-5p level was increased by tripterine in vivo. In conclusion, tripterine inhibits the growth, migration ability and invasiveness of HCC cells through intervening miR-532-5p/CXCL2.
Journal
|
CXCL2 (C-X-C Motif Chemokine Ligand 2)
|
CXCL2 elevation